ODTX
Odyssey Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.76
+8.94%Next report
Analyst consensus
- Next report date
- Sep 16, 2026
- EPS estimate
- -$0.83
- Revenue estimate
- —
Latest reported
- Last report date
- Jun 17, 2026
- EPS actual
- -$6.77
- EPS estimate
- -$1.11
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 0
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -508.0%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $38
- PT range
- $29 – $44
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026